{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:30:31Z","timestamp":1791804631410,"version":"4.3.4"},"reference-count":140,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>(1) Background: Myoinositol (MI) and D-chiro-inositol (DCI) are involved in a number of biochemical pathways within oocytes having a role in oocyte maturation, fertilization, implantation, and post-implantation development. Both inositols have a role in insulin signaling and hormonal synthesis in the ovaries. (2) Methods: Literature search (with key words: inositols, myo-inositol, d-chiro-inositol, PCOS) was done in PubMed until Sept. 2020 and 197 articles were identified, of which 47 were of clinical trials (35 randomized controlled trials). (3) Results: Many studies have demonstrated that in patients with polycystic ovarian syndrome (PCOS) MI treatment improved ovarian function and fertility, decreased the severity of hyperandrogenism including acne and hirsutism, positively affected metabolic aspects, and modulated various hormonal parameters deeply involved in the reproductive axis function and ovulation. Thus treating with MI has become a novel method to ameliorate PCOS symptoms, improve spontaneous ovulation, or induce ovulation. The current review is focused on the effects of MI and DCI alone or in combination with other agents on the pathological features of PCOS with focus on insulin resistance and adverse metabolic outcomes. (4) Conclusions: The available clinical data suggest that MI, DCI, and their combination in physiological ratio 40:1 with or without other compound could be beneficial for improving metabolic, hormonal, and reproductive aspects of PCOS.<\/jats:p>","DOI":"10.3390\/molecules25235566","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T09:16:49Z","timestamp":1606468609000},"page":"5566","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Inositols in PCOS"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4829-9449","authenticated-orcid":false,"given":"Zdravko","family":"Kamenov","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Clinic of Endocrinology University Hospital Alexandrovska, Medical University\u2014Sofia, 1431 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoaneta","family":"Gateva","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Clinic of Endocrinology University Hospital Alexandrovska, Medical University\u2014Sofia, 1431 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1210\/jc.2006-0178","article-title":"Positions statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline","volume":"91","author":"Azziz","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Teede, H.J., Deeks, A., and Moran, L.J. (2010). Polycystic ovary syndrome: A complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med., 8.","DOI":"10.1186\/1741-7015-8-41"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3389\/fendo.2020.00516","article-title":"Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions","volume":"11","author":"Aversa","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MED.0b013e328359ff92","article-title":"Reproductive impact of polycystic ovary syndrome","volume":"19","author":"Usadi","year":"2012","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3109\/01674820903477593","article-title":"Polycystic ovary syndrome: A biopsychosocial understanding in young women to improveknowledge and treatment options","volume":"31","author":"Moran","year":"2010","journal-title":"J. Psychosom. Obstet. Gynecol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/humrep\/der071","article-title":"Is having polycystic ovary syndrome (PCOS) a predictor of poor psychological function including depression and anxiety","volume":"26","author":"Deeks","year":"2011","journal-title":"Hum. Reprod."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.fertnstert.2018.05.004","article-title":"International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"110","author":"Teede","year":"2018","journal-title":"Fertil. Steril."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome","volume":"81","author":"Chang","year":"2004","journal-title":"Fertil. Steril."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.4158\/EP15748.DSC","article-title":"American association of clinical endocrinologists, American college of endocrinology, and androgen excess and PCOS society disease state clinical review: Guide to the best practices in the evaluation and treatment of polycystic ovary syndrome\u2013part 1","volume":"21","author":"Goodman","year":"2015","journal-title":"Endocr. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1210\/er.2015-1104","article-title":"The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited","volume":"37","author":"Rosenfield","year":"2016","journal-title":"Endocr. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.2174\/0929867325666171205144119","article-title":"Uterine Function: From Normal to Polycystic Ovarian Syndrome Alterations","volume":"25","author":"Ferreira","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41367-019-0009-1","article-title":"Obesity Programs of nutrition, Education, Research and Assessment (OPERA) group. Female infertility: Which role for obesity?","volume":"9","author":"Gambineri","year":"2019","journal-title":"Int. J. Obes. Suppl."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1210\/en.2019-00101","article-title":"Physiological and Pathological Androgen Actions in the Ovary","volume":"160","author":"Astapova","year":"2019","journal-title":"J. Endocrinol."},{"key":"ref_14","first-page":"165","article-title":"Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women","volume":"84","author":"Legro","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_15","first-page":"2694","article-title":"A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome","volume":"83","author":"Legro","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1210\/jc.2003-030219","article-title":"Glucose-to-Insulin Ratio Rather than Sex Hormone-Binding Globulin and Adiponectin Levels Is the Best Predictor of Insulin Resistance in Nonobese Women with Polycystic Ovary Syndrome","volume":"88","author":"Ducluzeau","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.fertnstert.2006.01.024","article-title":"Failure of the homeostatic model assessment calculation score for detecting metabolic deterioration in young patients with polycystic ovary syndrome","volume":"86","author":"Fulgeshu","year":"2006","journal-title":"Fertil. Steril."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.metabol.2003.10.032","article-title":"Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals","volume":"53","author":"McLaughlin","year":"2004","journal-title":"Metabolism"},{"key":"ref_19","first-page":"774","article-title":"Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis","volume":"18","author":"Dunaif","year":"1997","journal-title":"Endocr. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/306347","article-title":"Cardiovascular Risk Factors in Bulgarian Patients with Polycystic Ovary Syndrome and\/or Obesity","volume":"2012","author":"Gateva","year":"2012","journal-title":"Obstet. Gynecol. Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/humrep\/15.6.1266","article-title":"Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome","volume":"15","author":"Vauhkonen","year":"2000","journal-title":"Hum. Reprod."},{"key":"ref_22","first-page":"1421","article-title":"Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity","volume":"82","author":"Ciaraldi","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1093\/humrep\/dem302","article-title":"Evidence of subpopulations with different levels of insulin resistance in women with polycystic ovary syndrome","volume":"22","author":"Vigil","year":"2007","journal-title":"Hum. Reprod."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejogrb.2012.05.037","article-title":"Markers of visceral obesity and cardiovascular risk in patients with polycystic ovarian syndrome","volume":"164","author":"Gateva","year":"2012","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/jc.2004-1045","article-title":"Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome","volume":"90","author":"Apridonidze","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1043-2760(02)00612-4","article-title":"The role of lifestyle modification in polycystic ovary syndrome","volume":"13","author":"Norman","year":"2002","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1210\/jc.2007-1834","article-title":"Impact of Obesity on the Risk for Polycystic Ovary Syndrome","volume":"93","author":"Yildiz","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/sj.ijo.0801994","article-title":"Obesity and the polycystic ovary syndrome","volume":"26","author":"Gambineri","year":"2002","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.tem.2007.07.003","article-title":"Abdominal adiposity and the polycystic ovary syndrome","volume":"18","year":"2007","journal-title":"Trends Endocrinol. Metabol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1365-2265.2007.02954.x","article-title":"Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): A prospective study of 634 women with PCOS","volume":"67","author":"Panidis","year":"2007","journal-title":"Clin. Endocrinol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2265.1990.tb03897.x","article-title":"Effects of lute inizing hormone, insulin, insulin-like growth factor-I and ins ulin-like growth fac tor small bind ing protein I in the polycystic ovary syndrome","volume":"33","author":"Conway","year":"1990","journal-title":"Clin. Endocrinol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2265.1993.tb02376.x","article-title":"The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries","volume":"39","author":"Robinson","year":"1993","journal-title":"Clin. Endocrinol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJM199608293350902","article-title":"Decreases in Ovarian Cytochrome P450c17\u03b1 Activity and Serum Free Testosterone after Reduction of Insulin Secretion in Polycystic Ovary Syndrome","volume":"335","author":"Nestler","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00006254-199805000-00018","article-title":"Lean Women with Polycystic Ovary Syndrome Respond to Insulin Reduction With Decreases in Ovarian P450c17 alpha Activity and Serum Androgens","volume":"53","author":"Nestler","year":"1998","journal-title":"Obstet. Gynecol. Surv."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1210\/endo-123-2-733","article-title":"Insulin-Like Growth Factor I and Insulin Potentiate Luteinizing Hormone-Induced Androgen Synthesis by Rat Ovarian Thecal-Interstitial Cells","volume":"123","author":"Cara","year":"1988","journal-title":"Endocrinology"},{"key":"ref_36","first-page":"1147","article-title":"Impaired adipocyte lipolysis in nonobese women with the polycystic ovary syndrome: A possible link to insulin resistance?","volume":"82","author":"Ek","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1210\/jcem-72-1-83","article-title":"A Direct Effect of Hyperinsulinemia on Serum Sex Hormone-Binding Globulin Levels in Obese Women with the Polycystic Ovary Syndrome","volume":"72","author":"Nestler","year":"1991","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_38","first-page":"2001","article-title":"Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system","volume":"83","author":"Nestler","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2337\/diab.38.9.1165","article-title":"Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome","volume":"38","author":"Dunaif","year":"1989","journal-title":"Diabetes"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.2337\/diab.41.10.1257","article-title":"Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome","volume":"41","author":"Dunaif","year":"1992","journal-title":"Diabetes"},{"key":"ref_41","first-page":"302","article-title":"Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries","volume":"81","author":"Willis","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2337\/diacare.29.02.06.dc05-1070","article-title":"Altered D-chiro-inositol urinary clearance in women with polycystic ovarian syndrome","volume":"29","author":"Baillargeon","year":"2006","journal-title":"Diabetes Care"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/humrep\/deh609","article-title":"Impaired insulindependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries","volume":"20","author":"Rice","year":"2005","journal-title":"Hum. Reprod."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1172\/JCI108400","article-title":"Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome","volume":"57","author":"Rebar","year":"1976","journal-title":"J. Clin. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-2265.1989.tb00446.x","article-title":"Heterogeneity of the polycystic ovary syndrome: Clinical, endocrine and ultrasound features in 556 patients","volume":"30","author":"Conway","year":"1989","journal-title":"Clin. Endocrinol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem-52-2-231","article-title":"Increased luteinising hormone sensitivity to dopamine inhibition in the polycystic ovary syndrome","volume":"52","author":"Quigley","year":"1981","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1365-2265.1984.tb00114.x","article-title":"Evidence for decreased endogenous dopamine and opioid inhibitory influences on LH secretion in polycystic ovary syndrome","volume":"20","author":"Cumming","year":"1984","journal-title":"Clin. Endocrinol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1210\/jcem-62-5-904","article-title":"Insulin Stimulates Androgen Accumulation in Incubations of Ovarian Stroma Obtained from Women with Hyperandrogenism","volume":"62","author":"Barbieri","year":"1986","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0022-3476(85)80623-5","article-title":"Low levels of sex hormone-binding globulin in obese children","volume":"107","author":"Dunkel","year":"1985","journal-title":"J. Pediatr."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1210\/endo-108-4-1441","article-title":"Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells","volume":"108","author":"Adashi","year":"1981","journal-title":"Endocrinology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1530\/eje.0.1310641","article-title":"Insulin, insulin-like growth factor I (IGF-I) and IGF-II enhance basal and gonadotrophin-releasing hormone-stimulated luteinizing hormone release from rat anterior pituitary cells in vitro","volume":"131","author":"Soldani","year":"1994","journal-title":"Eur. J. Endocrinol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/endo-122-2-581","article-title":"The Effects of Experimental Hyperinsulinemia on Steroid Secretion, Ovarian [125 I]Insulin Binding, and Ovarian [125 I]Insulin-Like Growth-Factor I Binding in the Rat","volume":"122","author":"Poretsky","year":"1988","journal-title":"Endocrinology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/edrv.20.4.0374","article-title":"The insulin-related ovarian regulatory system in health and disease","volume":"20","author":"Poretsky","year":"1999","journal-title":"Endocr. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0303-7207(99)00239-7","article-title":"Follicular dynamics in the polycystic ovary syndrome","volume":"163","author":"Franks","year":"2000","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1210\/jc.2005-1457","article-title":"Relative Prevalence of Different Androgen Excess Disorders in 950 Women Referred because of Clinical Hyperandrogenism","volume":"91","author":"Carmina","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1210\/jcem-65-3-499","article-title":"Characterization of Groups of Hyperaiidrogenic Women with Acanthosis Nigricans, Impaired Glucose Tolerance, and\/or Hyperinsulinemia","volume":"65","author":"Dunaif","year":"1987","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2265.2007.02764.x","article-title":"Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: Implications for the management of polycystic ovary syndrome","volume":"66","author":"Barber","year":"2007","journal-title":"Clin. Endocrinol."},{"key":"ref_58","first-page":"2248","article-title":"Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome","volume":"82","author":"Taylor","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/1968450","article-title":"Inositols in Insulin Signaling and Glucose Metabolism","volume":"2018","author":"Bevilacqua","year":"2018","journal-title":"Int. J. Endocrinol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/jn\/117.2.397","article-title":"Handbook of Vitamins: Nutritional, Biochemical, and Clinical Aspects","volume":"117","author":"Halsted","year":"1987","journal-title":"J. Nutr."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1301\/00296640260042748","article-title":"Involvement of Inositol in Reproduction","volume":"60","author":"Beemster","year":"2002","journal-title":"Nutr. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s13105-016-0517-1","article-title":"Myo-inositol inhibits intestinal glucose absorption and promotes muscle glucose uptake: A dual approach study","volume":"72","author":"Chukwuma","year":"2016","journal-title":"J. Physiol. Biochem."},{"key":"ref_63","first-page":"3572","article-title":"Modulation of myo-[3H]inositol uptake by glucose and sorbitol in cultured bovine lens epithelial cells. II. Characterization of high- and low-affinity myo-inositol transport sites","volume":"33","author":"Cammarata","year":"1992","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0006-8993(90)90170-G","article-title":"Myo-inositol transport into endothelial cells derived from nervous system microvessels","volume":"511","author":"Kollros","year":"1990","journal-title":"Brain Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/1849162","article-title":"Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials","volume":"2016","author":"Unfer","year":"2016","journal-title":"Int. J. Endocrinol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/17425255.2020.1737675","article-title":"Experts\u2019 opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: A further help for human reproduction and beyond. Expert Opin","volume":"16","author":"Facchinetti","year":"2020","journal-title":"Drug Metab. Toxicol."},{"key":"ref_67","first-page":"237","article-title":"The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment","volume":"318","author":"Romero","year":"2020","journal-title":"Am. J. Physiol. Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJM199904293401703","article-title":"Ovulatory and metabolic effects of D-chiroinositol in the polycystic ovary syndrome","volume":"340","author":"Nestler","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1177\/1933719113518985","article-title":"Hyperinsulinemia Alters Myoinositol to d-chiroinositol Ratio in the Follicular Fluid of Patients With PCOS","volume":"21","author":"Unfer","year":"2014","journal-title":"Reprod. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-3-319-23865-4_13","article-title":"The Ratio of MI to DCI and Its Impact in the Treatment of Polycystic Ovary Syndrome: Experimental and Literature Evidences","volume":"3","author":"Facchinetti","year":"2016","journal-title":"Front. Gynecol. Endocrinol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Unfer, V., DiNicola, S., Lagan\u00e0, A.S., and Bizzarri, M. (2020). Altered Ovarian Inositol Ratios May Account for Pathological Steroidogenesis in PCOS. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197157"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4103\/2230-8210.189231","article-title":"The inositols and polycystic ovary syndrome","volume":"20","author":"Kalra","year":"2016","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1016\/j.fertnstert.2011.05.027","article-title":"The D-chiro-inositol paradox in the ovary","volume":"95","author":"Carlomagno","year":"2011","journal-title":"Fertil. Steril."},{"key":"ref_74","first-page":"1","article-title":"Metabolism and Ovarian Function in PCOS Women: A Therapeutic Approach with Inositols","volume":"2016","author":"Rossetti","year":"2016","journal-title":"Int. J. Endocrinol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3389\/fphar.2017.00341","article-title":"Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols","volume":"8","author":"Sortino","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_76","first-page":"153","article-title":"Insulin-lowering drugs in polycystic ovary syndrome. Obstet. Gynecol","volume":"28","author":"Iuorno","year":"2001","journal-title":"Clin. North. Am."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1530\/EJE-11-0840","article-title":"Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome","volume":"166","author":"Sabbadin","year":"2012","journal-title":"Eur. J. Endocrinol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1080\/09513590903015544","article-title":"Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome","volume":"25","author":"Caputo","year":"2009","journal-title":"Gynecol. Endocrinol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/09513590801893232","article-title":"Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweith patients with polycystic ovary syndrome","volume":"24","author":"Genazzani","year":"2008","journal-title":"Gynecol. Endocrinol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/09513590.2011.564685","article-title":"The effect of a combination therapy with myo-inositol and combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine and clinical parameterd in polycystic ovarian syndrome","volume":"27","author":"Minozzi","year":"2011","journal-title":"Gynecol. Endocrinol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/09513590.2012.743020","article-title":"Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study","volume":"29","author":"Artini","year":"2013","journal-title":"Gynecol. Endocrinol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/3204083","article-title":"A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women","volume":"2016","author":"Benelli","year":"2016","journal-title":"Int. J. Endocrinol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1530\/EC-17-0243","article-title":"Myo-inositol effects in women with PCOS: A meta-analysis of randomized controlled trials","volume":"6","author":"Unfer","year":"2017","journal-title":"Endocr. Connect."},{"key":"ref_84","first-page":"30","article-title":"Effectiveness of myoinositol for polycystic ovary syndrome: A systematic review and meta-analysis","volume":"59","author":"Zeng","year":"2017","journal-title":"Endocrinology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00404-020-05696-y","article-title":"\u00c1ngel Metabolic impact of current therapeutic strategies in Polycystic Ovary Syndrome: A preliminary study","volume":"302","author":"Groar","year":"2020","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/09513590.2018.1540578","article-title":"Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): A meta-analysis of randomized clinical trials","volume":"35","author":"Facchinetti","year":"2019","journal-title":"Gynecol. Endocrinol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1080\/09513590.2018.1540570","article-title":"Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: A randomized controlled clinical trial","volume":"35","author":"Shokrpour","year":"2019","journal-title":"Gynecol. Endocrinol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/09513590.2018.1549656","article-title":"Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: Randomized controlled trial","volume":"35","author":"Agrawal","year":"2019","journal-title":"Gynecol. Endocrinol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/1473612","article-title":"Myo-Inositol in the Treatment of Teenagers Affected by PCOS","volume":"2016","author":"Pkhaladze","year":"2016","journal-title":"Int. J. Endocrinol."},{"key":"ref_90","first-page":"347","article-title":"Randomized, double blind placebo-controlled trial: Effects of myo-inositol on ovarian function and metabolic factors in women with PCOS","volume":"11","author":"Gerli","year":"2007","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3109\/09513590.2012.685205","article-title":"Differential insulin response to myo-inositol administration in obese polycystic ovarian syndrome patients","volume":"28","author":"Genazzani","year":"2012","journal-title":"Gynecol. Endocrinol."},{"key":"ref_92","first-page":"575","article-title":"The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone","volume":"16","author":"Nordio","year":"2012","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_93","first-page":"537","article-title":"The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients","volume":"17","author":"Minozzi","year":"2013","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_94","first-page":"2293","article-title":"Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome","volume":"23","author":"Metro","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5603\/GP.2019.0002","article-title":"Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS)","volume":"90","author":"Januszewski","year":"2019","journal-title":"Ginekol. Polska"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1472-6483(10)60248-9","article-title":"Treatment of hirsutism with myo-inositol: A prospective clinical study","volume":"17","author":"Minozzi","year":"2008","journal-title":"Reprod. Biomed."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/3206872","article-title":"Different Effects of Myoinositol plus Folic Acid versus Combined Oral Treatment on Androgen Levels in PCOS Women","volume":"2016","author":"Ozay","year":"2016","journal-title":"Int. J. Endocrinol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Regidor, P.-A., Schindler, A.E., Lesoine, B., and Druckman, R. (2018). Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature. Horm. Mol. Biol. Clin. Investig., 34.","DOI":"10.1515\/hmbci-2017-0067"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1080\/09513590701672405","article-title":"Myo-inositol in patients with polycystic ovary syndrome: A novel method for ovulation induction","volume":"23","author":"Papaleo","year":"2007","journal-title":"Gynecol. Endocrinol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.fertnstert.2008.01.088","article-title":"Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial","volume":"91","author":"Papaleo","year":"2009","journal-title":"Fertil. Steril."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/09513590903366996","article-title":"Insulin sensitizer agents alone and in co-treatmentwithrFSH for ovulation induction in PCOS women","volume":"26","author":"Raffone","year":"2010","journal-title":"Gynecol. Endocrinol."},{"key":"ref_102","unstructured":"Ciotta, L., Iozza, I., Rubbino, G., Iemmola, A., Lizzio, I., Teodoro, M.C., and Palumbo, M. (2010, January 4\u20137). Treatment of hyperandrogenism by myo-inositol. Proceedings of the 14th World Congress of Gynecological Endocrinology, Firenze, Italy."},{"key":"ref_103","unstructured":"Di Berardino, O.M., Monteleone, P., Valentino, V., Ruggiero, M., Papini, F., Cela, V., Artini, P.G., and Genazzani, A.R. (2010, January 4\u20137). Myo-inositol administration in pcos patients after IVF. Proceedings of the 14th World Congress of Gynecological Endocrinology, Firenze, Italy."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/09513590.2014.964640","article-title":"Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance","volume":"31","author":"Kamenov","year":"2015","journal-title":"Gynecol. Endocrinol."},{"key":"ref_105","unstructured":"Papaleo, E., De Santis, L., Baillargeon, J., Zacche, M., Fusi, F., Brigante, C., and Ferrari, A. (2008, January 6\u20139). Comparison of myo-inositol plus folic acid vs clomiphene citrate for first line treatment in women with polycystic ovary syndrome. Proceedings of the 24th Annual Meeting of ESHRE, Barcelona, Spain."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1016\/j.fertnstert.2011.01.035","article-title":"The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen","volume":"95","author":"Morgante","year":"2011","journal-title":"Fertil. Steril."},{"key":"ref_107","first-page":"151","article-title":"Effects of inositol on ovarian function and metabolic factors in women with PCOS: A randomized double blind placebo-controlled trial","volume":"7","author":"Gerli","year":"2004","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_108","first-page":"105","article-title":"Metabolic and hormonal effects of myoinositol in women with polycystic ovarian syndrome: A double-blind trial","volume":"13","author":"Costantino","year":"2009","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/9537632","article-title":"Myoinositol as a Safe and Alternative Approach in the Treatment of Infertile PCOS Women: A German Observational Study","volume":"2016","author":"Regidor","year":"2016","journal-title":"Int. J. Endocrinol."},{"key":"ref_110","first-page":"23","article-title":"Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: Effects on body composition","volume":"64","author":"Alibrandi","year":"2012","journal-title":"Minerva Ginecol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"9387","DOI":"10.1002\/jcp.27623","article-title":"Myo-inositol and D-chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model","volume":"234","author":"Bevilacqua","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_112","first-page":"5512","article-title":"The 40:1 myo-inositol\/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: Comparison with other ratios","volume":"23","author":"Nordio","year":"2019","journal-title":"Eur Rev. Med. Pharmacol Sci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1080\/09513590.2019.1576620","article-title":"Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: A randomized controlled trial","volume":"8","author":"Mendoza","year":"2019","journal-title":"Gynecol. Endocrinol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/09513590.2019.1681959","article-title":"High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: A randomized controlled trial","volume":"36","author":"Mendoza","year":"2020","journal-title":"Gynecol. Endocrinol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/6461254","article-title":"Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary","volume":"2020","author":"Roseff","year":"2020","journal-title":"Int. J. Endocrinol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"558.e1","DOI":"10.1016\/j.ajog.2011.03.021","article-title":"Pregnancy outcomes in women with polycystic ovary syndrome: A metaanalysis","volume":"204","author":"Kjerulff","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1530\/EC-18-0076","article-title":"Polycystic ovary syndrome and risk factors for gestational diabetes","volume":"7","author":"Mustaniemi","year":"2018","journal-title":"Endocr. Connect."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.3109\/14767058.2015.1121478","article-title":"Myo-inositol may prevent gestational diabetes onset in overweight women: A randomized, controlled trial","volume":"29","author":"Santamaria","year":"2015","journal-title":"J. Matern. Neonatal Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/AOG.0000000000000958","article-title":"Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women: A Randomized Controlled Trial","volume":"126","author":"Scilipoti","year":"2015","journal-title":"Obstet. Gynecol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3109\/14767058.2013.766691","article-title":"Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: A randomized controlled trial","volume":"26","author":"Matarrelli","year":"2013","journal-title":"J. Matern. Neonatal Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3109\/09513590.2011.633665","article-title":"Myo-inositol may prevent gestational diabetes in PCOS women","volume":"28","author":"Rizzo","year":"2012","journal-title":"Gynecol. Endocrinol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/j.1464-5491.2011.03284.x","article-title":"The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes","volume":"28","author":"Corrado","year":"2011","journal-title":"Diabet. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/cen.13366","article-title":"Comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in polycystic ovary syndrome: A randomized controlled clinical trial","volume":"87","author":"Jamilian","year":"2017","journal-title":"Clin. Endocrinol."},{"key":"ref_124","first-page":"146","article-title":"Expert\u2019s opinion: Integrative treatment with inositols and lipoic acid for insulin resistance of PCOS. Gynecol","volume":"1","author":"Genazzani","year":"2020","journal-title":"Reprod. Endocrinol. Metab."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/09513590.2015.1014784","article-title":"Dchiro-inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS","volume":"31","author":"Cianci","year":"2015","journal-title":"Gynecol. Endocrinol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/193229681000400218","article-title":"Effects of Controlled-Release Alpha Lipoic Acid in Lean, Nondiabetic Patients with Polycystic Ovary Syndrome","volume":"4","author":"Masharani","year":"2010","journal-title":"J. Diabetes Sci. Technol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1080\/09513590.2018.1540573","article-title":"Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome","volume":"35","author":"Fruzzetti","year":"2019","journal-title":"Gynecol. Endocrinol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/09513590.2020.1737007","article-title":"Effect of d-chiro-inositol and alpha-lipoic acid combination on COH outcomes in overweight\/obese PCOS women","volume":"36","author":"Artini","year":"2020","journal-title":"Gynecol. Endocrinol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1080\/09513590.2017.1313972","article-title":"Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action","volume":"33","author":"Immediata","year":"2017","journal-title":"Gynecol. Endocrinol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/09513590.2019.1640673","article-title":"Long-term treatment with \u03b1-lipoic acid and myo-inositol positively affects clinical and metabolic features of polycystic ovary syndrome","volume":"36","author":"Fruzzetti","year":"2020","journal-title":"Gynecol. Endocrinol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2901393","DOI":"10.1155\/2020\/2901393","article-title":"Clinical and Metabolic Effects of Alpha-Lipoic Acid Associated with Two Different Doses of Myo-Inositol in Women with Polycystic Ovary Syndrome","volume":"2020","author":"Fruzzetti","year":"2020","journal-title":"Int. J. Endocrinol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1080\/09513590.2019.1640200","article-title":"Differential insulin response to oral glucose tolerance test (OGTT) in overweight\/ obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both","volume":"35","author":"Genazzani","year":"2019","journal-title":"Gynecol. Endocrinol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1080\/09513590.2020.1725967","article-title":"HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS) and decreases after treatment with myo-inositol (MYO) in combination with alpha-lipoic acid (ALA)","volume":"36","author":"Cirillo","year":"2020","journal-title":"Gynecol. Endocrinol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1080\/01443615.2019.1604644","article-title":"Efficacy of combination therapy of inositols, antioxidants and vitamins in obese and non-obese women with polycystic ovary syndrome: An observational study","volume":"40","author":"Advani","year":"2019","journal-title":"J. Obstet. Gynaecol."},{"key":"ref_135","first-page":"8687","article-title":"Efficacy of the synergic action of myoinositol, tyrosine, selenium and chromium in women with PCOS","volume":"23","author":"Oliva","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13048-019-0500-x","article-title":"Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: A pilot study","volume":"12","author":"Troisi","year":"2019","journal-title":"J. Ovarian Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/09513590.2015.1101444","article-title":"Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome","volume":"32","author":"Pacchiarotti","year":"2016","journal-title":"Gynecol. Endocrinol."},{"key":"ref_138","first-page":"8529","article-title":"The effect of myo-inositol, vitamin D3 and melatonin on the oocyte quality and pregnancy in in vitro fertilization: A randomized prospective controlled trial","volume":"24","author":"Wdowiak","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_139","unstructured":"Unfer, F. (2020). Inostol resistance\u2014A problem and a solution. Inositols\u2014Guide to Practical Applications in Obstetrics and Gynecology, A.G.UN.CO Obstetrics and Gynecology Center."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13048-018-0411-2","article-title":"Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women","volume":"11","author":"Oliva","year":"2018","journal-title":"J. Ovarian Res."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/23\/5566\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:38:15Z","timestamp":1760179095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/23\/5566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,27]]},"references-count":140,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["molecules25235566"],"URL":"https:\/\/doi.org\/10.3390\/molecules25235566","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,27]]}}}